ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non–small cell lung cancer (mNSCLC) with high PD-L1 levels

Journal article

Peer reviewed

Mark M. Awad, Mihaela Munteanu, Yufan Zhao, Lu Xu, Ayman Samkari and Luis G. Paz-Ares

Journal of clinical oncology, v 36(15_suppl), pp TPS9109-TPS9109

20 May 2018

Additional Links

Abstract only

11 Record Views

Title: ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non–small cell lung cancer (mNSCLC) with high PD-L1 levels
Creators: Mark M. Awad - Dana-Farber Cancer Institute
Mihaela Munteanu - Incyte (United States)
Yufan Zhao - Incyte (United States)
Lu Xu - Merck & Co., Inc., Rahway, NJ, USA (United States)
Ayman Samkari - Merck & Co., Inc., Rahway, NJ, USA (United States)
Luis G. Paz-Ares - Hospital Universitario 12 De Octubre
Publication Details: Journal of clinical oncology, v 36(15_suppl), pp TPS9109-TPS9109
Resource Type: Journal article
Language: English
Academic Unit: Pediatrics
Web of Science ID: WOS:000442916008013
Other Identifier: 991021838705604721

This publication has contributed to the advancement of the following goals:

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Web of Science research areas: Oncology